CliffBio
small molecule

RELEXXII

METHYLPHENIDATE HYDROCHLORIDE

Loss of exclusivityFebruary 2037latest FDA-listed patent expiry
CompanyOsmotica Pharmaceutical →View the full company profile on CliffBio

Drug detail

Brand nameRELEXXII
Active ingredientMETHYLPHENIDATE HYDROCHLORIDE
Strength36MG
Dosage formTABLET, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalJune 2022
Marketing statusRX

Listed patents

PatentExpiresType
10695336February 2037use U-4032
10265308February 2037product
9855258February 2037product
9827234February 2037use U-4032
9707217February 2037product

More from Osmotica Pharmaceutical

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

RELEXXII patent cliff — loss of exclusivity February 2037 | CliffBio